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KEKURANGAN Puma DAN Noxa BAGI MELANOMAGENESIS DALAM 
MODEL MENCIT MELANOMA 
 
ABSTRAK 
 
Kegagalan sel melanoma untuk menjalani apoptosis (sejenis kematian 
sel terancang) sebagai respon terhadap rawatan konvensional seperti 
dadah sitotoksik, dipercayai merupakan sebab utama melanoma menunjukkan 
rintangan terhadap terapi. Kajian bagi menentukan sumbangan laluan apoptosis 
intrinsik biasanya diterhad dengan penggunaan model kultur sel in vitro 
dan xenograf. Model mencit melanoma, Cdkn2a -/-, Tyr-HRASG12V, telah 
digunakan dalam projek ini bagi mangatasi masaalah tersebut. Model Cdkn2a -/-, 
Tyr-HRASG12V dikacukkan dengan baka Noxa -/- atau Puma -/- untuk 
menghasilkan Cdkn2a -/-, Tyr-HRASG12V, Noxa -/- dan Cdkn2a -/-, Tyr-
HRASG12V, Puma -/- masing masing. Generasi baka ini membolehkan kami 
menyiasat kepentingan laluan apoptosis intrinsik bagi genesis melanoma. Protein 
terhad BH3 Puma dan Noxa telah dipilih sebagai protein relevan untuk 
dieksploitasikan dalam laluan apoptosis atas bukti dari kajian lain yang 
melaporkan penglibatan mereka dalam biologi melanoma dan respon rawatan. Di 
sini, kami melaporkan bahawa tumor dari semua ketiga-tiga kohort disahkan sebagai 
melanoma melalui pengggunaan stain petanda standard emas HMB45, S100 and 
MelanA. Kehilangan Puma memecut melanomagenesis berbanding dengan kohort 
kawalan tetapi hanya secara marginal. Sebaliknya, kehilangan Noxa mengurangkan 
insiden melanoma, menunda genesis melanoma dan mengurangkan bilangan 
melanoma berbanding dengan baka kawalan dan Puma -/-. Tambahan pula, sebaik 
xv 
 
sahaja melanoma tumbuh dalam mencit Noxa -/-, melanoma membesar dengan kadar 
yang lebih perlahan berbanding dengan melanoma dalam kohort kawalan dan kohort 
Puma -/-. Walaupun melanoma sering tumbuh di bahagian telinga, bilangan 
melanoma di bahagian telinga kohort Noxa -/-, ternyata lebih kurang berbanding 
dengan dua kohort yang lain. Pertumbuhan tumor intrakranial dalam kohort Puma -/- 
adalah di luar jangkaan kami. Ini menunjukkan bahawa ketiadaan Puma boleh 
menyumbang kepada pertumbuhan tumor yang jarang ini. Kami mengemukakan dua 
hipotesis sebagai kemungkinan bagi kelewatan genesis melanoma dalam kohort 
Noxa -/- (1) pampasan lampau oleh protein terhad BH3 yang mempunyai potensi 
yang lebih tinggi (e.g. Puma, Bim atau Bid) ataupun (2) kesan bersepadu antara dua 
protein terhad BH3.  
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DEFECIANCY OF Puma AND Noxa FOR MELANOMAGENESIS IN A 
MOUSE MODEL OF MELANOMA 
 
ABSTRACT 
   
 It is commonly believed without sufficient evidence that the impairment of 
the ability to undergo apoptosis (a mode of programmed cell death) in response to 
conventional treatment such as cytotoxic drugs, gained melanoma its notorious 
resistance to therapy. Studies to determine the contribution of the intrinsic apoptosis 
pathway for melanomagenesis are often deterred by utilisation of in vitro cell culture 
models and xenograft models. An established mouse model of melanoma, the 
Cdkn2a -/-, Tyr-HRASG12V, was utilised in this study to obviate limitations posted by 
the usage of in vitro and xenograft models. The Cdkn2a -/-, Tyr-HRASG12V was 
crossed with either a Puma -/- or Noxa -/- line yielding in Cdkn2a-/-, Tyr-HRASG12V, 
Noxa -/- or Cdkn2a -/-, Tyr-HRASG12V, Puma -/- strains respectively. Generation of 
these strains enabled us to investigate the significance of the intrinsic apoptosis 
pathway for melanomagenesis. The BH3-only proteins Puma and Noxa were chosen 
as relevant proteins to be exploited in the apoptosis pathway as there are evidence 
from other studies reporting on their involvement in melanoma biology and treatment 
response. Here, we report that tumours from all three cohorts were stained for gold 
standard markers HMB45, S100 and MelanA and were confirmed as melanoma. 
Loss of Puma only marginally accelerated melanomagenesis compared to the control 
cohort. On the other hand, loss of Noxa decreased melanoma incidence, delayed 
melanomagenesis and decreased number of melanomas compared to the controls and 
Puma -/- cohorts. Upon establishment, melanomas in the Noxa -/- mice, grew 
xvii 
 
relatively slower compared to melanomas in the control and Puma -/- cohorts. 
Although melanoma frequently established on ears, the Noxa -/- cohort developed 
significantly less ear melanomas compared to the other two cohorts. Unexpectedly, 
the Puma -/- cohort developed intracranial tumours which indicates that absence of 
Puma could contribute to the onset of these infrequent tumours. We hypothesise two 
possibilities for the delay in melanomagenesis in the Noxa -/- cohort (1) 
overcompensation by more potent BH3-only proteins (e.g. Puma, Bim or Bid) or (2) 
a concerted effect between two BH3-only proteins. 
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CHAPTER 1 
 
INTRODUCTION 
 
Melanoma is a type of skin cancer which despite being low in occurrence, is 
high in its contribution to death tolls due to its nature of being resistant to therapy 
and high metastasising capacity (Surveillance, Epidemiology and End Results 
(SEER), 2015). Melanoma can be divided into two subtypes namely the chronically 
sun-damaged (CSD) melanoma and non-CSD melanoma. CSD melanoma is usually 
caused by mutation due to overexposure to UV radiation while the non-CSD 
melanoma is commonly hereditary (reviewed by Shain and Bastian, 2016). The 
stages of the progression of melanoma are characterised by various genetic 
mutations, among which, mutation in the BRAF and CDKN2A genes being the few 
most common (Tucker et al., 1997, Ciarletta et al., 2011).  
Number of reported cases of melanoma has been on the rise and has increased 
by 200% since 1973 (Reed et al., 2012) with Australia and New Zealand being the 
two countries with the highest record of melanoma patients in the world (Australian 
Institute of Health and Welfare (AIHW), 2014). Melanoma in many nations affects 
the younger population at large and, is most common among those aged 15 to 49 
(Cancer Registration Statistics, England, 2013). Melanoma, albeit being scarce, 
accounts for 0.4% of the total number of male cancer patients and 0.3% of the total 
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number of female cancer patients in the year 2007, in Malaysia (Omar and Ibrahim 
Tamin, 2011). 
Efforts to fight melanoma has also been increased in parallel to the increasing 
number of melanoma patients. A number of drugs have been approved by the U.S. 
Food and Drug Administration (FDA) for melanoma treatment thus far but the effort 
is not spared from further complication with the involvement of mutation in multiple 
pathways and the diversity of tumours. Melanoma cells are believed to be resistant to 
anti-cancer drugs due to their resistance to apoptosis, which is commonly assumed to 
be mediated by tumour suppressor protein p53 (reviewed by Brown and Attardi, 
2005). Hence, cells that are resistant to apoptosis due to mutations in p53 are 
expected to be recalcitrant to drugs (reviewed by Brown and Attardi, 2005). 
However, mutation of p53 is rare in melanoma (Soengas and Lowe, 2003). Why then 
are melanoma still insusceptible to drugs? With these apposing notions, the role of 
apoptosis in melanomagenesis is questionable. Thus, an appropriate model is needed 
to address this notion. 
The 2D, 3D and xenograft models, despite their many advantages, falls short 
in several ways in mimicking human melanoma. The 2D models is deprived of the 
natural environment for cell growth while the 3D model lacks the impairment of the 
immune system which are of vital importance for tumour development (Beaumont et 
al., 2014). The xenograft models which require transplantation of cells, subject cells 
to strong selection for defective apoptosis (Beaumont et al., 2014). Disadvantages in 
the rest of the models will be overcome in this project by using the Cdkn2a-/-, Tyr-
HRASG12V mouse model of melanoma. The Cdkn2a-/-, Tyr-HRASG12V which mimics 
common mutations in human melanoma will be crossed with either a Puma or Noxa 
deleted mice line, to abrogate the apoptosis pathway. Results of the crossing will be 
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the generation of Cdkn2a-/-, Tyr-HRASG12V, Noxa -/- and Cdkn2a -/-, Tyr-HRASG12V, 
Puma -/- strain respectively. The pro-apoptotic protein genes Noxa (phorbol-12-
myristate-13-acetate-induced protein 1) and Puma (p53 up-regulated modulator of 
apoptosis) were selected as the representative genes from the apoptosis pathway to 
be manipulated due to their common association in melanoma biology and treatment 
response. 
 The predisposed genetically modified mouse model will provide us an avenue 
to assess the degree of involvement of defective intrinsic apoptosis pathway for 
melanomagenesis through detailed observation of the consequences of the earlier 
mentioned genetic modifications. We hypothesised that loss of the pro-apoptotic 
protein genes Noxa or Puma will to lead to faster appearance, more rapid and 
invasive growth of melanoma in the mouse model. 
The rationale of this work stemmed from the preliminary data that were 
obtained from Centenary Institute, Sydney, Australia. Preliminary data showed that 
rather than accelerating melanomagenesis, loss of Noxa delayed the onset of 
melanoma, decreased melanoma penetrance and melanoma burden. Given the 
number of mice in the cohort was low, the effect of loss of Noxa on 
melanomagenesis might be a statistical fluke. Hence, significantly larger 
experimental groups would be required to attain better statistical significance and 
draw a more confident conclusion and this is what is aimed to be achieved in this 
project. We generated 32 Noxa -/- mice and 21 mice Puma -/- mice. In total, we had 
44 mice in the Noxa -/- cohort (32 mice generated in AMDI + 12 mice generated in 
Sydney) and 39 mice in the Puma -/- cohort (21 mice generated in AMDI + 18 mice 
generated in Sydney). Unfortunately, we could not generate more Cdkn -/- mice as 
the Cdkn -/- line was lost most probably due to error in breeding in Australia before 
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the mice were imported to AMDI, USM, Penang. Therefore, data showed for the 
Cdkn -/- cohort in this chapter, were data generated in Sydney, Australia as none was 
bred in Malaysia.  
Preliminary study of gene expression, particularly the expression of selected pro- and 
anti-apoptotic genes in mice tumours will be conducted. Cell lines will also be 
derived from mice tumours for the use in other probable future work.  
1.1 Objectives 
 
Objective 1: To investigate the effect of loss of pro-apoptotic genes, Puma and Noxa 
for melanomagenesis in a predisposed mouse model of melanoma.  
 
Objective 2: To investigate changes in levels of the other pro and anti–apoptotic 
proteins in the intrinsic apoptosis pathway when either Noxa or Puma is 
manipulated.  
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CHAPTER 2 
 
 
LITERATURE REVIEW 
 
 
Incidences of skin cancers have been on the rise over the past decade. 
Approximately 76,380 cases of melanoma have been diagnosed in the year 2016 
(American Cancer Society, Cancer Facts and Figures, 2016). While accounting for 
only less than 2% of all skin cancers, melanoma is responsible for a large majority of 
skin cancer deaths due to its resistance to therapy and highly metastatic nature 
(Surveillance, Epidemiology and End Results (SEER), 2015). In order to understand 
melanoma, we shall first get to know our skin. 
2.1 Getting acquainted with our skin – The Three Prong Fork 
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Figure 2.1 Cross section of the skin. The skin can be divided into three major layers 
namely, the subcutis (layer 1), dermis (layer 2) and epidermis layer (layer 3). The 
subcutis layer binds the skin to adjacent organs and contains fat tissue for energy 
storage. The dermis consists of mostly connective tissues and is important for 
thermal and nutrient regulation due to the rich network of blood and lymphatic 
vessels. The outer most layer is the epidermis which contains the pigment melanin, 
produced by melanocytes which gives rise to the colour of our skin. Melanin protects 
living cells from DNA damage or mutations caused by UV radiation. Melanocytes, 
keratinocytes and the pigment melanin are shown in the magnification bubble. 
 
 Think of the skin as a fork made up of three prongs, each with their individual 
important roles but nonetheless, interconnected. The first prong, the subcutis or 
subcutaneous layer, is the inner most layer of the skin which binds the skin to the 
adjacent organs through loose connective tissues (Mescher, 2013) (Figure 2.1). This 
layer contains adipocytes that stores energy (Mescher, 2013). 
 The second prong, the dermis consists of two sub-layers – the papillary layer 
and the reticular layer consists of mostly connective tissue (McGrath and Uitto 2010, 
Mescher, 2013). The dermis region supports the epidermis layer and connects it to 
the subcutaneous tissue (Kolarsick et al., 2011) (Figure 2.1). This layer of the skin 
plays an important role in nutritive and thermoregulatory functions due to the rich 
network of blood and lymphatic vessels (Mescher, 2013). 
 The third and final prong is the outer most layer of the skin called epidermis 
(Figure 2.1). The epidermis layer is further divided into several subcutaneous layers 
(Mescher, 2013). The deepest layer, named stratum basale contains melanocytes 
which are the melanin producing cells (reviewed by Shain and Bastian, 2016) (Figure 
2.1 – see magnification bubble). Melanin, a pigment which gives rise to skin colour 
is contained in a cytoplasmic organelle called melanosome and transported to the 
most superficial layer of the epidermis called the stratum corneum (Mescher, 2013). 
At the stratum corneum, melanosomes accumulate within keratinocytes. 
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Keratinocytes are matured basal cells which act as protective barrier of living cells 
against environmental threats such as virus, bacteria, fungi and water loss as well as 
UV radiation (reviewed by Shain and Bastian, 2016). Melanin within the 
keratinocytes absorb and scatter UV radiation as harmless heat to protect living cells 
from DNA damage or mutation (Mescher, 2013). Having said that, exposure to UV 
radiation remains the major risk factor for development of melanoma. Exposure to 
UV weakens the immune system and aids in the formation of DNA damaging 
reactive oxygen species (ROS). Other risk factors which contribute to melanoma 
include family history of melanoma, previous diagnosis of melanoma, 
immunosuppression and multiple benign (>100) or dysplastic nevi (>6) (Rigel and 
Carucci, 2000, Miller and Mihm, 2006, Ibrahim and Haluska, 2009).  
 
2.2 Introduction to melanoma   
 Melanoma originates in the melanocytes and is the deadliest skin cancer as it 
highly metastatic and therapy resistant. Melanoma can be divided into two subtypes 
namely the chronically sun-damaged (CSD) melanoma and non-CSD melanoma 
(reviewed by Shain and Bastian, 2016). The CSD melanoma are highly associated to 
mutation and damage done by UV radiation through primarily high levels of sun 
exposure and thus occupies areas such as the head and neck which are most exposed 
to the sun in comparison to other parts of the body (reviewed by Shain and Bastian, 
2016). CSD melanoma are usually diagnosed in patients over the age of 50 (Bastian, 
2014). On the other hand, the non-CSD melanoma are commonly hereditary. The 
presence of epidermal nevus which are commonly known as moles or birthmarks, 
often increases the risk of melanoma in young patients, usually in the first decade of 
human life (reviewed by Criscito et al., 2016, Shain and Bastian, 2016). Mutations in 
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CSD melanoma are usually of the NRAS and BRAFnonV600E while mutation in non-
CSD melanoma are commonly of the BRAFV600E  (Curtin  et al., 2005). However, 
mutation which causes melanoma is not only confined to the genes mentioned above, 
but may affect many other proteins in pathways which controls cell proliferation 
such as NF1 (Krauthammer et al., 2015) and cell cycle control such as the CDKN2A 
which encodes tumour suppressor proteins p16INK4A and p14ARF (Fargnoli et al., 
1998). The CDKN2A and CDK4 located on chromosome 9p21 and 12q14 
respectively are strongly associated with family history of melanoma (Meyle and 
Guldberg, 2009). The CDKN2A gene locus will be further elaborated in section 2.6. 
The major potential cause of CSD melanoma is sun exposure, in the form of 
UVA and UVB (Gandini et al., 2005). Penetration of UVB is enhanced by the 
increasing depletion of the ozone layer leading to a higher risk for UV-induced 
carcinogenesis (Fabo, 2005). The risks of melanoma is also on the rise with the rising 
popularity of sunbedding for aesthetic purposes (The International Agency for 
Research on Cancer Working Group on artificial ultraviolet and skin, 2007). Non-
CSD melanoma usually caused by other endogenous risk factors of skin cancer such 
as number of melanocytic nevi, phototype, skin and eye colour, presence of 
dysplastic nevi, and personal history or hereditary of skin cancer (Fagundo et al., 
2011).  
 The evolution of melanoma occurs in five stages based on the Clark model 
(Wallace et al., 1984). An illustration of the stepwise progression of melanoma is as 
shown in Figure 2.2. The first stage, the benign melanocyte nevi is the commonly 
acquired mole caused by the proliferation of normal melanocytes. The second stage 
of the progression, the dysplastic nevus, is caused by BRAF mutation in pre-existing 
nevus or at a new location. This stage is characterised by the formation of random 
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and asymmetric lesions of multiple pigmentation with irregular border (Tucker et al., 
1997). Dysplastic nevus which experience genetic mutation, for instance, a silenced 
CDKN2A tumour suppressor gene with an activated MAPK pathway will progress to 
the radial growth phase (RGP). Cells at this phase will acquire the ability to 
proliferate intra-epidermally, but have no ability to metastasise and is confined to the 
epidermis (Ciarletta et al., 2011). With the loss of E-cadherin, the progression enters 
the vertical growth phase (VGP) where cells acquire the ability to invade the dermis 
and subcutaneous tissue. The final stage of the progression is metastatic melanoma 
that can spread to other areas of the body, usually first to lymph nodes then to skin, 
subcutaneous soft tissue, lungs, liver and the brain (Ibrahim and Haluska, 2009).  
 
Adapted from: McMaster Pathophysiology Review  
Figure 2.2 Stepwise evolution of melanoma based on the Clark model. Stage 1: 
Benign nevus, Stage 2: Dysplastic nevus; Stage 3: RGP; Stage 4: VGP; Stage 5: 
Metastatic melanoma. Once melanoma cells are independent from the control of 
keratinocytes, they breach the basement membrane and are able to interact with 
fibroblasts, lymphatic and vascular endothelial cells, which allow them to eventually 
invade to other areas of the body. 
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2.3         Melanoma around the world  
 
Incidences of melanoma is definitely of no stranger to the society and have 
caused deaths in a large part of the world both in the northern and southern region of 
the globe, especially within the Caucasian populations. New Zealand and Australia 
are the two countries with the highest number of melanoma in the world (Australian 
Institute of Health and Welfare (AIHW), 2014). It was estimated that one person 
becomes a victim of melanoma in every six hours in Australia specifically in 
Queensland (Australian Institute of Health and Welfare (AIHW), 2014). A ratio of 
71 out of 10,000 people in the year 2009 to 2013 was diagnosed with melanoma in 
Queensland alone, exceeding all the other number of cases reported worldwide 
(Australian Institute of Health and Welfare (AIHW), 2014).  
A recent study reported on the projection of future melanoma incidences in 
six populations (US whites and populations of the United Kingdom, Sweden, 
Norway, Australia and New Zealand) (Whiteman et al., 2016).  Melanoma 
incidences in the US whites and the populations of the UK, Sweden and Norway 
have always been in the rise and are projected to continue increasing until 2022. 
Melanoma burden in Australia has been declining at -0.7% each year since 2005 but 
is still on the rise in New Zealand although it is estimated to decline soon (Whiteman 
et al., 2016). Nonetheless, new melanoma cases are projected to increase in all six 
populations because of the longer age expectancy (Whiteman et al., 2016). Moving 
to South America, in Brazil, 1,073 (543 male patient, 530 female patient) cases of 
melanoma was reported in 2015 (Vazquez et al., 2015).  
 Unlike the aforementioned countries, melanoma is rare in Malaysia. 
According to the National Cancer Registry Report, 2007, a total of 61 cases of 
melanoma was reported (Omar and Ibrahim Tamin, 2011). Among the 61 cases 
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reported, 34 were males - 11 Malay, 10 Chinese and 2 Indians. Out of the total of 27 
female melanoma patients, 14 of them were Malays, 11 were Chinese and one Indian 
(Omar and Ibrahim Tamin, 2011). In a study conducted at the University Malaya 
Medical Centre from 1998 to 2008, 32 cases of cutaneous melanoma were recorded 
within the ten years of the study among which, the largest group of 19 people were 
Chinese patients, followed by 10 Malays and 3 Indians (Pailoor et al., 2012). 
According to a news report from the Star newspaper in February 2015, data from the 
Dermatology Clinic, Hospital Kuala Lumpur from year 2006 to 2014, revealed that 
melanoma is uncommon in Malaysia as it only accounted for 5.4% of the patients in 
the Dermatology Clinic of Hospital Kuala Lumpur.  
 
2.4 Therapies for melanoma  
Survival rate of melanoma falls drastically once it enters the metastatic stage 
(Coventry et al., 2015). Melanoma among all skin cancers, has possibly the highest 
proficiency to spread to other parts of the body and is resistant to many therapies 
(Wu and Singh, 2011, Braeuer et al., 2014). Treatment methods of melanoma is 
usually given based on the stage of melanoma. Some treatment methods include 
surgery, immunotherapy, radiation therapy, chemotherapy and targeted therapies.  
 Melanoma at the early stage is usually treated by surgery. However, adjuvant 
therapy with drugs is needed when melanoma has metastasised to other parts of the 
body. Dacarbazine (DTIC) was among the first drug to be developed for the 
treatment of metastatic melanoma in 1975. However, treatment of melanoma went 
into to its dark age for the next 20 years as no other drug was developed until the 
year 1995. A better understanding of the role of the immune system in 
melanomagenesis, brought to the development of three drugs namely Intron A, 
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Proleukin and Sylatron for treatment of metastatic melanoma. From then onwards, 
development of drugs for treatment of melanoma took flight with more 
understanding of proteins and signalling pathway mutations (e.g. BRAF) involved in 
melanomagenesis (eg. Zelboraf, Mekinis, Tafinlar). Over the years, a number of 
drugs have been approved by the U.S. Food and Drug Administration (FDA) for 
melanoma treatment to be used as single agent or in combination.  
As many cancer researchers are embracing the personalised medicine 
approach for cancer treatments and care, existing cancer treatment drugs have been 
exploited for their potential in this treatment approach. Personalised medicine utilises 
understanding of the unique genetic and clinical information of each individual 
patient at a molecular level in order to optimise the strategy used for their treatment 
and health care (Chan and Ginsburg, 2011, Foroutan B, 2015). 
 In personalised medicine, drugs are given to patients according to the type of 
genetic alteration in the various pathways involved in melanomagenesis among 
which the common ones are the MAPK (mitogen-activated protein kinases) and 
PI3K/AKT (phosphatidylinositol-4,5-bisphosphate 3-kinase/ protein kinase B) 
signalling pathways. The MAPK pathway allows the transfer of signals from the 
receptor on the surface of a cell to the cell’s DNA through a chain of proteins, while 
the PI3K/AKT pathway regulates cell cycle in response to extracellular signals 
(reviewed by Sun et al., 2015, Maryu et al., 2016). Regulation of the pathway often 
involve cross-talking with other signalling pathways such as the MAPK pathway 
(Mendoza et al., 2011). Both these pathways are important in signaling apoptosis, 
cell proliferation and growth (reviewed by Chang et al., 2003, Sun et al., 2015, 
Maryu et al., 2016). As such, mutation in either or both of these pathways result in 
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development of cancer (reviewed by Pappalordo et al., 2016). The MAPK pathway is 
further elaborated in section 2.5 reflecting its focus in this project. 
Drugs such as vemurafenib (Chapman  et al., 2011) and trametinib (Infante et 
al., 2012) which are specific inhibitors of BRAF and the MAPK pathway 
respectively, have been widely used in the field of targeted therapies in personalised 
medicine with remarkable responses. Imatinib has been used for treatment of 
melanoma patients with C-KIT gene (activated KIT transmits signal via the MAPK 
pathway (reviewed by Zhang and Liu, 2002) alterations (Hodi et al., 2008). Despite 
the great early outcome, tumours treated with these inhibitors become irresponsive to 
their specific inhibitors due to additional alterations in the MAPK pathway namely 
mutations in neuroblastoma RAS viral oncogene homolog (NRAS) (Nazarian et al., 
2010) and mitogen-activated protein kinase (MEK) (Wagle et al., 2011), 
amplifications or slice variants of BRAF (Whittaker et al., 2010, Poulikakos et al., 
2011, Shi et al., 2012) or CRAF (Montagut et al., 2008) (Figure 2.3). Other 
resistance factors include loss of neurofibromatosis (NF1) (negative regulator of the 
ras signal transduction pathway) (Whittaker et al., 2013, Maertens et al., 2013), 
increased expression of Cancer Osaka Thyroid (COT) (a MAPK antagonist) 
(Johannessen et al., 2010), upregulation of receptor tyrosine kinases namely the beta-
type platelet-derived growth factor receptor (PDGFRβ) (Nazarian et al., 2010) and 
insulin-like growth factor 1 (IGF-1R) (Villanueva et al., 2010) which activates the 
PI3K/AKT pathway or loss of tumour suppressor protein, phosphatase and tensin 
homolog (PTEN) (PTEN inhibits the activation of the PI3K/AKT pathway) (Paraiso 
et al., 2011). In order to overcome resistance, current treatment strategies aim at 
treating melanoma cells with combination of MAPK and PI3K pathway inhibitors.  
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Besides targeting the proliferative pathways (e.g. MAPK and/or PI3K/AKT 
pathway(s)), the BCL-2 family proteins, the critical regulators of the intrinsic 
apoptosis pathway, have also gained attention as attractive therapeutic targets for 
melanoma treatment. The interest to target these proteins mounted with the 
development of small molecule inhibitors such as ABT-737 and now ABT-263 
(Navitoclax, AbbVie) which specifically target these proteins. The BCL-2 family 
proteins became ideal targets for treatment, given the perception that melanoma cells 
are exceptionally resistant to apoptosis. Based on this perception, substantial amount 
of time and cost were invested in developing antisense BCL-2 and BH3 mimetics to 
target melanoma cells. Although much time and effort were invested in developing 
drugs to target the BCL-2 proteins, there is surprisingly very little effort focused on 
understanding the contribution of the intrinsic apoptosis pathway for melanoma 
biology and whether it affects drug resistance. The broad aim of the project is to 
understand the contribution of the intrinsic apoptosis pathway for melanoma biology 
and drug resistance. This project particularly focuses on comprehending the 
involvement of the intrinsic apoptosis pathway for melanomagenesis. These points 
will be further expanded in the following sections, which will first introduce the 
MAPK pathway, CDKN2A gene locus and BCL-2 family members. The last two 
sections will discuss the missing link between the intrinsic apoptosis pathway and 
melanomagenesis, and the advantages of using genetically engineered mouse models 
in our study.  
 
2.5 The Mitogen Activated Protein Kinase (MAPK) Pathway 
The MAPK pathway (Figure 2.3) is involved in a variety of fundamental 
cellular processes and is frequently abrogated in melanoma. The pathway is activated 
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by a number of growth factors including Stem Cell Factor (SCF), Fibroblast Growth 
Factor (FGF) and Hepatocyte Growth Factor (HGF) (Bohm et al., 1995) which 
stimulate membrane-bound receptor tyrosine kinases (RTKs). Activation of RTK, 
phosphorylates RAS. There are three isoforms of RAS: HRAS, NRAS and KRAS 
(Castellano and Santos, 2011). Activated RAS phosphorylates RAF which is a 
serine/threonine kinase (Figure 2.3). Similar to RAS, RAF has three isoforms: 
ARAF, BRAF and RAF1 (also known as CRAF) (reviewed by An et al., 2015). 
Phosphorylated RAF in turn phosphorylates another serine/threonine kinase, MEK 
(exists as two isoforms: MEK1 and MEK2). Activated MEK phosphorylates ERK 
which exists as two isoforms ERK1 and ERK2 (reviewed by Buscà et al., 2016)  
(Figure 2.3). ERK1 and 2 induce genes that are involved in cell proliferation and 
protects cells from being apoptosed (Sekulic et al., 2008, Haass et al., 2008). 
 Constitutive activation of the HRAS transgene in the melanocyte lineage was 
required for the manifestation of spontaneous melanoma in the Cdkn2a -/- mouse 
model. Requirement for the constitutive activation of the HRAS transgene, reiterates 
the importance of the MAPK pathway for melanoma establishment. The constitutive 
activation of the HRAS transgene recapitulates the activation of the MAPK pathway 
in human melanomas as would normally occur by mutations in NRAS and BRAF. 
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Figure 2.3 The Mitogen Activated Protein Kinase (MAPK) Pathway. The 
pathway is activated by various growth factors which stimulate membrane bound 
receptor tyrosine kinases (RTKs). Activation of RTK, phosphorylates RAS. 
Phosphorylated RAS phosphorylates MEK which in turn phosphorylates ERK. 
 
 
2.6 The CDKN2A gene locus 
The CDKN2A (Cyclin-Dependent Kinase Inhibitor 2A) gene encodes two 
distinct tumour suppressor proteins with overlapping reading frames p16INK4A (cyclin 
dependent kinase inhibitor 2A) and p14ARF (alternative reading frame) (Ouelle et al., 
1995). P19ARF is the mouse homolog of human p14ARF (Fecher et al., 2007). 
Mutation in the CDKN2A gene locus which is common in familial melanoma can 
occur in either or both of the p16INK4A or p14ARF gene causing deregulation of cell 
cycle progression (reviewed by Zhao et al., 2016). The p16INK4A tumour suppressor 
protein inhibits the phosphorylation of the Retinoblastoma protein (pRb). PRb in its 
hypophosphorylated form, inhibits the E2F transcription factor and represses 
induction of genes required for cells to enter the S phase from the G1 cell cycle 
phase (reviewed  by Zhao et al., 2016) (Figure 2.4). P16INK4A loss leads to 
hyperphosphorylation of the pRb protein which in turn liberates E2F. E2F then 
induces genes which are required for the unscheduled entry of cells into S phase 
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from G1 (reviewed by Zhao et al., 2016) (Figure 2.4). The ARF tumour suppressor 
protein stabilises p53 by inhibiting MDM2 (human homolog HDM2). P53 senses cell 
stress signals such as DNA damage caused by chemotherapeutic drugs and activate 
the apoptosis pathway (Figure 2.7). In the absence of ARF, MDM2 targets p53 for 
degradation through the ubiquitin-proteasome pathway (reviewed by Pant and 
Lozano, 2014) (Figure 2.4). 
 
 
 
 
Adapted from: Griewank et al., 2014 
Figure 2.4 The CDKN2A gene locus. Products of the CDKN2A gene locus, p16INK4A 
and p14ARF negatively regulate the pRb (retinoblastoma protein) and p53 pathway 
respectively. Loss of the CDKN2A locus leads to uncontrolled cell proliferation and 
evasion from apoptosis. 
 
The mouse model of melanoma utilised in this study was established based on 
known history of mutation in the CDKN2A locus which is often found in familial 
melanoma (Hussussian et al., 1994, Kamb et al., 1994). In order to investigate the 
roles of p16Ink4a and p19Arf in melanoma, mice models harbouring deletions in either 
genes were established (Chin et al., 1997). Unfortunately the p16Ink4a null mice 
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developed melanoma with very low penetrance (Chin et al., 1997) and the p19Arf null 
mice developed zero melanomas (Chin et al., 1997). With the realisation that loss of 
either p16Ink4a or p19Arf is insufficient for melanomagenesis, the HRAS transgene, 
active in the melanocyte lineage was crossed to the initial models and this time, the 
established models developed spontaneous melanomas. The latency of melanoma 
formation was however, slow with median latencies of 40 weeks (Chin et al., 1997). 
The model was then improved by deleting both p16Ink4a and p19Arf with constitutive 
activation of the HRAS transgene (Chin et al., 1997, Chin et al., 1999). The improved 
model developed spontaneous melanoma with high frequency at a median latency of 
22 weeks thus confirming the importance of both p16Ink4a and p19Arf for melanoma 
suppression.  
 
2.7 The BCL-2 family members 
The BCL-2 family proteins are the key regulators of the intrinsic apoptotic 
pathway (reviewed by Delbridge et al., 2016). The members of the family share one 
or more of the BCL-2 homology (BH) domains namely, BH1, BH2, BH3 and BH4 
which give the members the ability to interact with one another (reviewed by 
Delbridge et al., 2016). The BCL-2 family members can be classified into two 
groups: anti-apoptotic proteins and pro-apoptotic proteins. The pro-apoptotic proteins 
can be further divided into the pro-apoptotic effector proteins, and the BH3-only pro-
apoptotic proteins (Figure 2.5). The BH3-only proteins, only share the BH3 domain 
with the rest of the sub-groups (Figure 2.5). The transmembrane (TM) domain which 
is present in all proteins with the exception of BFL-1, BAD, BID, BMF and PUMA, 
facilitates association of the proteins with the outer mitochondrial membrane (OMM) 
(reviewed by Delbridge et al., 2016) (Figure 2.5).  
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Figure 2.5 The BCL-2 family members and their BH domains. BCL-2 family 
members are divided into two groups: the anti-apoptotic proteins and the pro-
apoptotic proteins (effector proteins and BH3-only proteins). The anti-apoptotic and 
effector pro-apoptotic proteins contain all four BH domains while BH3-only pro-
apoptotic proteins only share the BH3 domain with the other proteins. The 
transmembrane (TM) domain which is usually present in all members except for 
BFL-1, BAD, BID, BMF and PUMA, facilitates association of the proteins with the 
outer mitochondrial membrane (OMM). 
 
The anti-apoptotic members are BCL-2 (B cell CLL/lymphoma-2), BCL-XL 
(BCL-2-related gene, long isoform), BCL-w (B-cell lymphoma-2 like protein), 
MCL-1 (myeloid cell leukaemia 1) and BFL-1/A1 (BCL-2-related gene A1) 
(reviewed by Delbridge et al., 2016). They have all the four BCL-2 homology 
domains (BH1 to 4) and inhibit cell death by binding to the BH3-only proteins or to 
activated BAK and BAX (reviewed by Llambi et al., 2011) (Figure 2.7).  
The pro-apoptotic effector proteins consist of BAX (BCL-2-associated X 
protein), BAK (BCL-2 antagonist killer) and BOK (Bcl-2 related ovarian killer) 
(reviewed by Delbridge et al., 2016).  BAX and BAK are ubiquitously expressed 
while the rest of the BCL-2 family members are tissue specific and is only expressed 
when stimulated (reviewed by Delbridge et al., 2016). BAX is a monomeric protein 
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in the cytosol that only travels to the mitochondria upon inactivation of the anti-
apoptotic proteins by the BH3-only proteins (Fröhlich et al., 2014). Activated BAX 
inserts into the OMM and oligomerises with BAK to induce MOMP (Gillies and 
Kuwana, 2014). The induction of MOMP by BAK and BAX can occur through 
either the formation of pore or ion channels by BAK and BAX (Lucken-Ardjomande 
and Martinou, 2005, Kinnally and Antonsson, 2007) or, through the unity of BAX 
and BAK with pre-existing ion channel(s) such as the voltage-dependant anion 
channel (VDAC) (Shimizu et al., 1999, Cheng et al., 2003). Expression of Bok is 
only found to be restricted to ovarian granulosa cells and several reproductive tissues 
characterized by hormonally regulated cyclic cell turnover (Hsu et al., 1997). Unlike 
BAX and BAK, BOK is not sensitive to antagonist effects of anti-apoptotic proteins 
and induces MOMP independently of other BCL-2 family members (reviewed by 
Llambi et al., 2016). These suggests that BOK is regulated hormonally and thus is 
only expressed in reproductive organs. 
 The BH3-only pro-apoptotic proteins only share the BH3 domain with the 
other members, hence their name. The members are: BAD (BCL-2-associated death 
promoter), BIK (BCL-2 interacting killer), Hrk (Harakiri), NOXA (Phorbol-12-
myristate-13-acetate-induced protein 1), PUMA (p53-up-regulated modulator of 
apoptosis), BID (BH3 interacting-domain death agonist), BIM (BCL-2-interacting 
mediator) and BMF (BCL-2 modifying factor) (reviewed by Kiraz et al., 2016). 
The BH3 domain is an amphipathic α-helix that serves as a binding motif for 
interaction with a hydrophobic groove on either multidomain anti- or pro-apoptotic 
BCL-2 family members (Shamas-Din et al., 2013). BID, BIM and PUMA are non-
selective and has binding motif that allows them to bind and inhibit all of the anti-
apoptotic proteins. BAD binds and inhibits BCL-2, BCL-XL and BCL-w. BIK and 
21 
 
Hrk bind to BCL-XL, BCL-w and BFL/A1. The binding motif on NOXA can only fit 
to the groove of MCL-1 and BFL1/A1 thus, making NOXA’s inhibition specific to 
MCL-1 and BFL1/A1 only (reviewed by Besbes et al., 2015) (Figure 2.6).  
 
 
 
Figure 2.6 Selective inhibition of the anti-apoptotic proteins by some members 
of the BH3-only proteins. PUMA, BID and BIM inhibit all anti-apoptotic proteins. 
HRK and BIK inhibit BCL-XL, BCL-w and BFL-1/A1. BAD and BMF inhibit BCL-
2, BCL-XL and BCL-w. NOXA specifically inhibits MCL-1 and BFL-1/A1. Yellow 
boxes: BH3-only pro-apoptotic proteins; purple boxes: anti-apoptotic proteins, solid 
lines: direct inhibition and different line colours indicate specific inhibition of the 
anti-apoptotic proteins by the BH3-only pro-apoptotic proteins. 
 
 
2.8 Apoptosis Pathways 
Apoptosis is a mode of programmed cell death. The pathway is important in 
the maintenance of normal cell turnover and proper function of the immune system, 
embryo development, hormone-dependant atrophy, and chemical induced cell death 
(reviewed by Onal et al., 2016). Abrogation of the pathway can lead to cancer 
manifestation or degenerative diseases (Tait and Green, 2010). Cells engage the 
apoptosis pathway following various stress signals, such as DNA damage or 
endoplasmic reticulum stress caused by chemotherapeutic agents, activation of 
oncogenes, growth-factor deprivation and ultraviolet radiation (reviewed by Mohana-
Kumaran et al., 2014). Apoptosis can be initiated through the intrinsic apoptosis 
pathway (the mitochondrial pathway) or extrinsic apoptosis pathway (death receptor 
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pathway). The extrinsic pathway will be briefly introduced and the intrinsic pathway 
and its associated proteins will be discussed at a greater length, reflecting the focus 
of this study.  
 
2.8.1 The Extrinsic Apoptosis Pathway 
Activation of the extrinsic pathway begins when death receptors (DR) located 
at the plasma membrane are activated by their respective ligands namely FASL, TNF 
and TRAIL. Members of the DR includes the tumour necrosis factor (TNF), related 
apoptosis-inducing ligand (TRAIL) receptor 1 (other names: DR4 and 
TNFRSF10A), TRIAL2 (other names: DR5 and TNRSF10B), FAS (other names: 
CD95 and APO1) and TNF receptor I (other name: TNFRSF1A) (reviewed by Ichim 
and Tait, 2016). The death receptors contain a cystolic “death domain” which 
enables them to interact with other cystolic proteins. Cystolic FADD (FAS-
associated death domain), caspases-8 and -10 are recruited by the receptors once the 
ligands bind to their respective death receptor (Figure 2.7). Activated caspase-8 in 
turn, activates executioner caspases-3 and -7 which initiate the proteolytic 
mechanism of apoptosis in cells (reviewed by Ichim and Tait, 2016) (Figure 2.7). 
The extrinsic pathway crosstalks with the intrinsic pathway through the actions of 
caspase-8. Caspase-8 truncates and activates BH3-only protein BID to its truncated 
form, tBID (Li et al., 1998, Luo et al., 1998). The pathway thereafter, follows the 
intrinsic pathway (Figure 2.7). 
 
2.8.2 The Intrinsic Apoptosis Pathway 
The intrinsic apoptosis pathway can be triggered by various extracellular and 
intracellular stresses such as DNA damage caused by chemotherapeutic agents, 
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growth factor deprivation, ultra violet radiation and oncogene activation (reviewed 
by Mohana-Kumaran et al., 2014). For example, damage in the DNA caused by 
chemotherapeutic agents lead to p53 accumulation in the cells. Accumulation of p53 
activate the BH3-only proteins. Induction of the BH3-only proteins lead to inhibition 
of the anti-apoptotic proteins (Figure 2.7). As a result, BAX and BAK oligomerise 
and induce mitochondrial outer membrane permeabilisation (MOMP) which leads to 
the release of cytochrome c (see section 2.7 on the possible mechanisms how BAX 
and BAK oligomerise and induce MOMP). Cytochrome c together with APAF-1, 
form apoptosome and activate initiator caspase-9 (Figure2.7). Activation of caspase-
9 in turn activates a series of executioner caspases-3, -6 and -7 and finally, activation 
of apoptosis in cells (Kiraz et al., 2016) (Figure 2.7).  
Caspases are a family of genes important for maintaining homeostasis 
through regulating cell death and inflammation (Enari et al., 1998). Caspases-3 and -
7 cleave a large set of substrates, for example, resulting in the characteristic 
morphological and biochemical characteristics of apoptosis such as nuclear 
condensation, phosphatidylserine exposure, and genomic DNA fragmentation 
(Lamkanfi and Kanneganti, 2010). For example, caspase-3 cleaves Inhibitor 
of Caspase Activated DNase (ICAD), causing CAD to become activated. CAD 
cleaves DNA and degradation of nucleus DNA results in apoptosis (Enari et al., 
1998). 
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Figure 2.7 The Apoptosis Pathways. The intrinsic pathway can be induced by the 
accumulation of p53 as a response to various cellular stresses. The accumulation of 
p53 protein activate the BH3-only pro-apoptotic proteins which in turn inhibit the 
anti-apoptotic proteins leading to BAX/BAK oligomerisation. The oligomerisation of 
effector proteins BAX/BAK induces MOMP resulting in cytochrome-c release to the 
cytoplasm. Cytochrome-c together with APAF-1 form the apoptosome and activate 
caspase-9. Activation of caspase-9, in turn activates executioner caspases-3, -6 and -
7 which consequences in apoptosis. The extrinsic apoptosis pathway is activated by 
death ligands and their individual death receptors which leads to the recruitment of 
FADD as well as caspases-8 and -10. Activated caspases-8 and -10 activate 
executioner caspases-3, -6, and -7 and subsequently, activation of apoptosis. The 
intrinsic and extrinsic pathway crosstalk through the actions of caspase-8. Caspase-8 
activates BH3-only protein, BID to its truncated form, tBID. Truncated BID activates 
BAX and BAK directly which leads to the activation of the intrinsic pathway. Solid 
lines: direct inhibition or activation, yellow boxes: BH3-only pro-apoptotic proteins, 
purple box: anti-apoptotic proteins, and skull: activation of apoptosis in the cell. 
 
2.9 Melanomagenesis and the Intrinsic Apoptosis Pathway – The Missing Link 
 It has been widely accepted without much evidence that treatment of cancer 
cells with chemotherapeutic drugs, induce apoptosis mediated by tumour suppressor 
protein p53. Hence, it is believed that cells that are resistant to apoptosis due to 
inactivation or loss of p53 will be recalcitrant to drugs (reviewed by Brown and 
